Almirall, S.A.
Records under this name other than the patents Almirall, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,051,851 | Inhaler for the Administration of Powdered Pharmaceuticals, and a Powder Cartridge System for Use with This Inhaler Formerly held In force · High confidence | In force | High confidence | |
| US 10,434,268 | Inhalation Device for Powdered Drugs Formerly held In force · High confidence | In force | High confidence | |
| US 10,512,740 | Inhalation Device for Powdered Drugs Formerly held In force · High confidence | In force | High confidence | |
| US 10,828,433 | Inhalation Device for Powdered Drugs Formerly held In force · High confidence | In force | High confidence | |
| US 12,441,704 | Compounds Active Towards Nuclear Receptors Formerly held In force · High confidence | In force | High confidence | |
| US 11,685,727 | Compounds Active Towards Nuclear Receptors Formerly held In force · High confidence | In force | High confidence | |
| US 11,780,843 | Compounds Active Towards Nuclear Receptors Formerly held In force · High confidence | In force | High confidence | |
| US 10,005,771 | New Bicyclic Derivatives Having BETA2 Adrenergic Agonist and M3 Muscarinic Antagonist Activities Lapsed on the fee record Ended Jun 26, 2026 · High confidence | Lapsed on the fee record | Ended Jun 26, 2026 | High confidence |
| US 8,242,177 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor Term ended Term ended May 17, 2026 · From the USPTO record | Term ended | Term ended May 17, 2026 | From the USPTO record |
| US 9,907,807 | Topical pharmaceutical compositions Lapsed on the fee record Ended Mar 6, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 6, 2026 | From the USPTO record |